.png)
In phase II ECOG-ACRIN E2211 trial, the addition of Capecitabine to Temozolomide significantly improved the progression-free survival (PFS) in patients with advanced, low or intermediate grade pancreatic #Neuroendocrine_Tumors (NETs). In the interim analysis, median PFS was 22.7 months in the capecitabine/temozolomide group vs 14.4 months in the temozolomide group (HR = 0.58, P = .022). In the final analysis, median OS was 53.8 months for temozolomide and 58.7 months for capecitabine/temozolomide (HR = 0.82, p = 0.42).
.png)